0000950170-24-106968.txt : 20240916 0000950170-24-106968.hdr.sgml : 20240916 20240916204634 ACCESSION NUMBER: 0000950170-24-106968 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240912 FILED AS OF DATE: 20240916 DATE AS OF CHANGE: 20240916 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Hughes-Wilson Alexandra CENTRAL INDEX KEY: 0002005875 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38452 FILM NUMBER: 241302324 MAIL ADDRESS: STREET 1: C/O MEREO BIOPHARMA STREET 2: 1 CAVENDISH PLACE CITY: LONDON STATE: X0 ZIP: W1G 0QF ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Mereo BioPharma Group plc CENTRAL INDEX KEY: 0001719714 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE CAVENDISH PLACE STREET 2: FOURTH FLOOR CITY: LONDON STATE: X0 ZIP: W1G0QF BUSINESS PHONE: 4403330237300 MAIL ADDRESS: STREET 1: ONE CAVENDISH PLACE STREET 2: FOURTH FLOOR CITY: LONDON STATE: X0 ZIP: W1G0QF FORMER COMPANY: FORMER CONFORMED NAME: Mereo Biopharma Group plc DATE OF NAME CHANGE: 20171016 4 1 ownership.xml 4 X0508 4 2024-09-12 0001719714 Mereo BioPharma Group plc MREO 0002005875 Hughes-Wilson Alexandra C/O MEREO BIOPHARMA GROUP PLC 4TH FLOOR, ONE CAVENDISH PLACE LONDON X0 W1G 0QF UNITED KINGDOM false true false false See Remarks false American Depositary Shares representing Ordinary Shares 2024-09-12 4 S false 7769 4.4727 D 190816 D American Depositary Shares representing Ordinary Shares 2024-09-12 4 S false 40029 4.4727 D 150787 D American Depositary Shares representing Ordinary Shares 2024-09-13 4 S false 16304 4.221 D 134483 D American Depositary Shares representing Ordinary Shares 2024-09-13 4 S false 84008 4.221 D 50475 D Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer. Represents the number of ADSs required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance-based restricted stock units under the issuer's 2019 Employee Incentive Plan (the 'Plan'), occurring on September 11, 2024. These sales are mandated by the Issuer's election under its Plan to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $4.37 to $4.62, inclusive. The Reporting Person undertakes to provide to Mereo BioPharma Group plc ("Mereo"), any security holder of Mereo, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of ADSs sold at each separate price within the ranges set forth in footnotes (3) and (4) to this Form 4. The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $4.01 to $4.43, inclusive. The Reporting Person sold a total of 124,037 ADSs solely to pay tax obligations, including tax withholding obligations related to the exercise of stock options described in the Form 4 filed on September 13, 2024. The total amount of securities beneficially owned on the reporting person's Form 4 filed on September 13, 2024 has been reduced by 44,296, which reflects ADSs withheld by the Issuer in connection with the net settlement of the stock option exercise on September 11, 2024 and inadvertently omitted from the September 13, 2024 filing. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3. Chief Patient Access and Commercial Planning /s/ Christine Fox, by power of attorney 2024-09-16